Figure 1. Potential model for reduced lenalidomide-sensitivity of Multiple Myeloma cells with high expression of CRBN target proteins like Ikaros, Aiolos and BSG.

High protein amounts prevent lenalidomide-induced degradation to critical low levels in the cells.